Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) – Analysts at Cantor Fitzgerald issued their FY2017 EPS estimates for Bellicum Pharmaceuticals in a note issued to investors on Tuesday, according to Zacks Investment Research. Cantor Fitzgerald analyst E. Piros anticipates that the biopharmaceutical company will earn ($3.07) per share for the year. Cantor Fitzgerald currently has a “Buy” rating and a $32.00 target price on the stock.
Other research analysts have also issued reports about the stock. Jefferies Group LLC restated a “buy” rating and issued a $19.00 target price (down from $22.00) on shares of Bellicum Pharmaceuticals in a report on Tuesday, March 14th. Zacks Investment Research upgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 17th. Finally, Wells Fargo & Co initiated coverage on shares of Bellicum Pharmaceuticals in a report on Wednesday, March 8th. They issued an “outperform” rating and a $29.50 target price on the stock. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $26.94.
COPYRIGHT VIOLATION NOTICE: “Bellicum Pharmaceuticals Inc Forecasted to Earn FY2017 Earnings of ($3.07) Per Share (BLCM)” was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.com-unik.info/2017/04/21/bellicum-pharmaceuticals-inc-forecasted-to-post-fy2017-earnings-of-3-07-per-share-blcm-updated-updated.html.
Bellicum Pharmaceuticals (NASDAQ:BLCM) traded down 4.01% during mid-day trading on Thursday, reaching $13.42. 576,044 shares of the company traded hands. The firm’s market capitalization is $364.45 million. Bellicum Pharmaceuticals has a 52 week low of $8.61 and a 52 week high of $23.11. The stock’s 50 day moving average price is $13.04 and its 200 day moving average price is $15.21.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings results on Monday, March 13th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by $0.03. The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.10 million. Bellicum Pharmaceuticals had a negative net margin of 19,399.12% and a negative return on equity of 49.65%. The firm’s quarterly revenue was up 135.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.63) EPS.
Several hedge funds and other institutional investors have recently made changes to their positions in BLCM. Baker BROS. Advisors LP bought a new position in shares of Bellicum Pharmaceuticals during the third quarter valued at $96,826,000. State Street Corp raised its position in shares of Bellicum Pharmaceuticals by 4.9% in the fourth quarter. State Street Corp now owns 326,037 shares of the biopharmaceutical company’s stock valued at $4,442,000 after buying an additional 15,142 shares during the last quarter. Eventide Asset Management LLC bought a new position in shares of Bellicum Pharmaceuticals during the fourth quarter valued at $3,405,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Bellicum Pharmaceuticals by 0.6% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 105,126 shares of the biopharmaceutical company’s stock valued at $2,092,000 after buying an additional 617 shares during the last quarter. Finally, Berson & Corrado Investment Advisors LLC bought a new position in shares of Bellicum Pharmaceuticals during the first quarter valued at $1,032,000. Institutional investors and hedge funds own 68.87% of the company’s stock.
In other news, Director Kevin M. Slawin sold 30,000 shares of the stock in a transaction dated Tuesday, February 7th. The shares were sold at an average price of $12.54, for a total transaction of $376,200.00. Following the transaction, the director now directly owns 84,206 shares in the company, valued at approximately $1,055,943.24. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Bros. Advisors Lp Baker acquired 166,666 shares of the business’s stock in a transaction dated Friday, March 24th. The shares were bought at an average price of $12.00 per share, for a total transaction of $1,999,992.00. The disclosure for this purchase can be found here. 23.30% of the stock is currently owned by corporate insiders.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Bellicum Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bellicum Pharmaceuticals Inc and related companies.